| Literature DB >> 31703943 |
Mohan S Kamath1, Mariano Mascarenhas2, Sebastian Franik3, Emily Liu4, Sesh Kamal Sunkara5.
Abstract
A growing list of clinical adjuncts are being used during in vitro fertilization (IVF) treatment. Most of these IVF add-ons (such as growth hormone, aspirin, heparin, dehydroepiandrostenedione, testosterone, male and female antioxidants, and screening hysteroscopy) are being introduced into routine clinical practice in a hurried manner without any clear evidence of benefit in most cases. These add-ons make the IVF more complicated and increase the overall cost for the treatment, which is borne by the couples and health care providers. Our current review found no high-quality evidence to support the use of these IVF add-ons in routine practice. Large, well-designed, randomized trials must be conducted to evaluate the effectiveness and safety of these interventions. There is also a pressing need to develop an evidence-dictated mechanism for introducing newer interventions into routine clinical settings.Entities:
Keywords: Clinical add-on; IVF add-on; IVF adjuvant; clinical adjunct
Mesh:
Substances:
Year: 2019 PMID: 31703943 DOI: 10.1016/j.fertnstert.2019.09.019
Source DB: PubMed Journal: Fertil Steril ISSN: 0015-0282 Impact factor: 7.329